🇬🇧·2d agoResearch
Filgotinib inhibits METTL3-mediated m 6 A of EIF3A by targeting ERG-TBP to suppress PDAC progression JAK-STAT3-independently
Publisher
n
npj Precision Oncology
UK
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on nature.com
Leave the platform to read the original full article on the publisher site.
Source: npj Precision Oncology
Scope: Research
Related coverage
More related coverage
Dana-Farber Cancer Institute·20h ago
Dana-Farber Preclinical Research Finds Opportunities for Treatment Improvements for HER2-positive Breast Cancer
Drugs that target human epidermal growth factor receptor 2 (HER2) have revolutionized the treatment...
npj Precision Oncology·1d ago
Multimodal AI model for early detection of hepatocellular carcinoma
npj Precision Oncology·2d ago
Neoadjuvant mFOLFOX6 plus camrelizumab and apatinib in colon cancer and biomarker research via spatiotemporal-omics profiling
npj Precision Oncology·2d ago